Page last updated on March 28, 2025
Coeptis Therapeutics Holdings, Inc. reported their cybersecurity risk management and governance process in a yearly 10-K filed on 2025-03-27 18:45:49 EDT.
Filings
10-K filed on 2025-03-27
Coeptis Therapeutics Holdings, Inc. filed a 10-K at 2025-03-27 18:45:49 EDT
Accession Number: 0001683168-25-001942
Note: filing items unformatted. Drop us a note with the above URL to help us prioritize formatting it!
Item 1C. Cybersecurity.
ITEM 1C. CYBERSECURITY Cybersecurity Risk Management and Strategy The Company recognizes the importance of cybersecurity in safeguarding its information systems and data. Our cybersecurity measures primarily rely on standard security protocols provided by Microsoft Outlook and OneDrive, which include encryption, multi-factor authentication, and access controls to protect against unauthorized access and data breaches. Given the evolving nature of cybersecurity threats, the Company monitors its systems for potential vulnerabilities and relies on third-party security updates and patches to mitigate risks. While we believe our current measures are appropriate for our operations, we acknowledge that no security system is entirely immune from potential threats, including phishing attacks, malware, ransomware, and unauthorized access. Governance and Oversight The Company’s executive management is responsible for overseeing cybersecurity risks and ensuring compliance with our security practices. At this time, the Company does not have a dedicated cybersecurity team but relies on its IT service providers and Microsoft’s security framework for system protection and incident response. Potential Risks and Impact Despite these measures, the Company may be vulnerable to cybersecurity incidents that could disrupt operations, compromise sensitive data, or result in financial or reputational harm. Any material cybersecurity incident would be assessed and disclosed as necessary.
Company Information
Name | Coeptis Therapeutics Holdings, Inc. |
CIK | 0001759186 |
SIC Description | Biological Products, (No Diagnostic Substances) |
Ticker | COEP - NasdaqCOEPW - Nasdaq |
Website | |
Category | Emerging growth company |
Fiscal Year End | December 30 |